CoChat

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently two drugs, pirfenidone and nintedanib, were approved for clinical use as they are able to slow down the disease progression. The mechanisms by which these two drugs act in in vitro cell systems are not known. The aim of this study was therefore to examine the effects of pirfenidone and nintedanib on fibroblasts and myofibroblasts structure and function established from patients with or without IPF. METHODS: Stromal cells were collected and cultured from control lung (n = 4) or IPF (n = 7). The cells were treated with pirfenidone and/or nintedanib and the effect of treatment was evaluated by measuring cell proliferation, alpha smooth muscle actin (α-SMA) and fibronectin expression by Western analysis and/or immunoelectron microscopy, ultrastructural properties by transmission electron microscopy and functional properties by collagen gel contraction and invasion assays. RESULTS: Both pirfenidone and nintedanib reduced in vitro proliferation of fibroblastic cells in a dose dependent manner. The number of cells from control lung was reduced to 47 % (p = 0.04) and of IPF cells to 42 % (p = 0.04) by 1 mM pirfenidone and correspondingly to 67 % (p = 0.04) and 68 % (p = 0.04), by 1 μM nintedanib. If both drugs were used together, a further reduced proliferation was observed. Both pirfenidone and nintedanib were able to reduce the amount of α-SMA and the myofibroblastic appearance although the level of reduction was cell line dependent. In functional assays, the effect of both drugs was also variable. CONCLUSIONS: We conclude that the ultrastructure and function of fibroblasts and myofibroblasts are affected by pirfenidone and nintedanib. Combination of the drugs reduced cell proliferation more than either of them individually. Human lung derived cell culture systems represent a potential platform for screening and testing drugs for fibrotic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-016-0328-5

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proliferation of stromal cells was reduced by pirfenidone (a, b) and by nintedanib (c, d). Six samples were analyzed of which 3 were derived from control lung (a, c) and 3 from IPF (b, d). Different concentrations of pirfenidone (0.1 mM-1 mM) or nintedanib (0.1-1 μM) were added to the cell culture at the beginning of the experiment. The values were related to the corresponding control. (*p < 0.05, **p < 0.01, KW test)
Fig. 1 Proliferation of stromal cells was reduced by pirfenidone (a, b) and by nintedanib (c, d). Six samples were analyzed of which 3 were derived from control lung (a, c) and 3 from IPF (b, d). Different concentrations of pirfenidone (0.1 mM-1 mM) or nintedanib (0.1-1 μM) were added to the cell culture at the beginning of the experiment. The values were related to the corresponding control. (*p < 0.05, **p < 0.01, KW test)CC BY · PubMed Central
Fig. 2 The amount of α-SMA was evaluated by Western analysis. A total of two cell lines derived from control lung and three cell lines derived from IPF lung were used for α-SMA quantification on day 3 (a). Pirfenidone reduced α-SMA expression significantly. One IPF derived sample was used to evaluate α-SMA expression after a single exposure to 0.5 mM pirfenidone or 0.5 μM nintedanib on days 2, 3 and 7 (b). (*p < 0.05, KW test)
Fig. 2 The amount of α-SMA was evaluated by Western analysis. A total of two cell lines derived from control lung and three cell lines derived from IPF lung were used for α-SMA quantification on day 3 (a). Pirfenidone reduced α-SMA expression significantly. One IPF derived sample was used to evaluate α-SMA expression after a single exposure to 0.5 mM pirfenidone or 0.5 μM nintedanib on days 2, 3 and 7 (b). (*p < 0.05, KW test)CC BY · PubMed Central
Fig. 3 Transmission electron microscopy analysis of stromal cells derived from control lung (a, c, e, g) or IPF lung (b, d, f, h). Under normal cell culture conditions a, b there were only occasional myofibroblast features detected. TGFβ1 (5 ng/ml) c, d increased the myofibroblastic appearance such as the extracellular filament bundle (EFB), intracellular actin filament (a) and dilated rough endoplasmic reticulum (RER). Both 0.5 mM pirfenidone (e, f) and 0.5 μM nintedanib (g, h) reduced the numbers of TGFβ1 induced myofibroblastic features. Scale bar is 1 μm
Fig. 3 Transmission electron microscopy analysis of stromal cells derived from control lung (a, c, e, g) or IPF lung (b, d, f, h). Under normal cell culture conditions a, b there were only occasional myofibroblast features detected. TGFβ1 (5 ng/ml) c, d increased the myofibroblastic appearance such as the extracellular filament bundle (EFB), intracellular actin filament (a) and dilated rough endoplasmic reticulum (RER). Both 0.5 mM pirfenidone (e, f) and 0.5 μM nintedanib (g, h) reduced the numbers of TGFβ1 induced myofibroblastic features. Scale bar is 1 μmCC BY · PubMed Central
Fig. 4 A representative of IEM of IPF derived cells (a-f) and quantification of α-SMA (g) and fibronectin (h). The cells were exposed to TGFβ1 (a, d), to TGFβ1 and pirfenidone (b, e) and to TGFβ1 and nintedanib (c, f). α-SMA (a-c) and fibronectin (d-f) expression can be localized by the presence of gold particles (black dots) by IEM. For evaluating the level of expression (g) and (h), the values of average numbers of gold particles in stromal cells derived from two control and two IPF lungs are shown. The concentrations used were 5 ng/ml TGFβ1, 0.5 mM pirfenidone and 0.5 μM nintedanib. Scale bar is 0.5 μm
Fig. 4 A representative of IEM of IPF derived cells (a-f) and quantification of α-SMA (g) and fibronectin (h). The cells were exposed to TGFβ1 (a, d), to TGFβ1 and pirfenidone (b, e) and to TGFβ1 and nintedanib (c, f). α-SMA (a-c) and fibronectin (d-f) expression can be localized by the presence of gold particles (black dots) by IEM. For evaluating the level of expression (g) and (h), the values of average numbers of gold particles in stromal cells derived from two control and two IPF lungs are shown. The concentrations used were 5 ng/ml TGFβ1, 0.5 mM pirfenidone and 0.5 μM nintedanib. Scale bar is 0.5 μmCC BY · PubMed Central
Fig. 5 Collagen gel contraction assay of IPF derived cells from two different patients are shown (a and b). The values shown are gel sizes compared to the original size. Averages of relative gel sizes related to the corresponding control at each time point of samples derived from seven patients with IPF (c). Relative values from four cell lines treated with TGFβ1 alone, TGFβ1 and pirfenidone or TGFβ1 and nintedanib (d). The concentrations used were 5 ng/ml TGFβ1, 0.5 mM pirfenidone and 0.5 μM nintedanib
Fig. 5 Collagen gel contraction assay of IPF derived cells from two different patients are shown (a and b). The values shown are gel sizes compared to the original size. Averages of relative gel sizes related to the corresponding control at each time point of samples derived from seven patients with IPF (c). Relative values from four cell lines treated with TGFβ1 alone, TGFβ1 and pirfenidone or TGFβ1 and nintedanib (d). The concentrations used were 5 ng/ml TGFβ1, 0.5 mM pirfenidone and 0.5 μM nintedanibCC BY · PubMed Central
Fig. 6 Invasion assay. Invasion percentages of both healthy control lung (white bar) and IPF lung (black bar) are shown with or without pirfenidone or nintedanib (a). Two IPF lung derived samples were exposed to TGFβ1, to TGFβ1 and pirfenidone, or to TGFβ1 and nintedanib (b)
Fig. 6 Invasion assay. Invasion percentages of both healthy control lung (white bar) and IPF lung (black bar) are shown with or without pirfenidone or nintedanib (a). Two IPF lung derived samples were exposed to TGFβ1, to TGFβ1 and pirfenidone, or to TGFβ1 and nintedanib (b)CC BY · PubMed Central
Fig. 7 Effect of combined therapy on cell proliferation. The stromal cells from four control lungs (a) and four IPF lungs (b) were treated with 0.5 mM pirfenidone, 0.5 μM nintedanib or both drugs simultaneously. (*p < 0.05, KW test)
Fig. 7 Effect of combined therapy on cell proliferation. The stromal cells from four control lungs (a) and four IPF lungs (b) were treated with 0.5 mM pirfenidone, 0.5 μM nintedanib or both drugs simultaneously. (*p < 0.05, KW test)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 133

Metadata

Authors
Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R.
Affiliations
  • Oulu University Hospital (FI)
  • University of Toronto (CA)
  • Karolinska Institutet (SE)
  • University of Eastern Finland (FI)
Corresponding author
Lehtonen, Siri T.
Venue
Respiratory Research
Published
2016-02-04
Volume
17
Issue
1
Pages
14-14
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2267777024
Cited by
133
References
35
Citations by year
2026: 6 · 2025: 9 · 2024: 4 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 7 · 2019: 15 · 2018: 22 · 2017: 19 · 2016: 5
FWCI
18.18
Type
journal article
Language
en
Open access
Locations
  • Respiratory Research (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion)
Funders
  • Foundation of the Finnish Anti-Tuberculosis Association
  • Jalmari and Rauha Ahokas Foundation
  • Väinö and Laina Kivi Foundation
  • Swedish-Finnish Cultural Foundation
  • Oulu University Hospital
  • Hjärt-Lungfonden
  • Otto A. Malm Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, pirfenidone, nintedanib, fibroblasts, myofibroblasts, fibroblast proliferation, alpha-smooth muscle actin, fibronectin, collagen gel contraction, cell invasion, combination therapy, antifibrotic agents, drug screening
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Cells, Cultured, Dose-Response Relationship, Drug, Drug Therapy, Combination, Fibroblasts, Humans, Indoles, Pyridones, Treatment Outcome, Cell Proliferation, Idiopathic Pulmonary Fibrosis, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-016-0328-5
The paper
Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R. (2016). Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-016-0328-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.